Pfizer Announces Topline Phase 2b Results of Oral GLP-1R …
WEBDec 1, 2023 · NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes.
Pfizer says it will advance once-daily GLP-1 pill after all
WEBJul 11, 2024 · P fizer said Thursday that it plans to advance a new, once-a-day formulation of its experimental obesity drug danuglipron, meant to be a pill version in the same class as popular injections like...
Pfizer Advances Development of Once-Daily Formulation of Oral …
WEBJul 11, 2024 · The ongoing open-label, randomized study is evaluating the pharmacokinetics and safety of immediate- and modified release formulations of danuglipron administered orally in healthy adults 18 years or older.
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist ...
WEBDec 1, 2023 · Twice-daily dosing of danuglipron showed statistically significant reductions from baseline in body weight for all doses, with mean reductions ranging from -6.9% to -11.7%, compared to +1.4% for...
Oral diabetes and obesity meds danuglipron and orforglipron …
WEBOct 17, 2023 · New orally-administered GLP-1 receptor agonists danuglipron and orforglipron show promise in treating type 2 diabetes and obesity, according to a systematic review.
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist ...
WEBDec 1, 2023 · Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity. December 1, 2023. Share. X. Join Pfizer Investor Insights. Sign up to receive important updates about Pfizer, how we’re innovating for patients and delivering value for shareholders.
Danuglipron (PF-06882961) in type 2 diabetes: a randomized ... - Nature
WEBJun 14, 2021 · We developed danuglipron (PF-06882961), an oral small-molecule GLP-1R agonist and found it had comparable efficacy to injectable peptidic GLP-1R agonists in a humanized mouse model.
Oral GLP-1 Drug Danuglipron to Move Forward, but With Tweaks …
WEBDec 1, 2023 · About half of patients with obesity but not diabetes who were enrolled in a phase IIb trial of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, dropped out due to side effects, Pfizer announced today.
Pfizer targets obesity with new once-daily danuglipron drug
WEBJul 11, 2024 · Pfizer announced that it has selected its preferred once-daily modified release formulation of danuglipron, a move that is significant in the obesity drug’s development.
Phase 2b Trial Suggests Efficacy of Oral Danuglipron for Glycemic ...
WEBMay 24, 2023 · New phase 2b clinical trial data suggest danuglipron, a novel, oral, small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist, demonstrated an efficacy and safety profile consistent with currently available peptide agonists in adults with type 2 diabetes (T2D). 1